Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice

Critical Care

Volumn 16, Issue 6, 2012, Pages

  Oudemans van Straaten, Heleen M ^a   Ostermann, Marlies ^b  

^a Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CITRIC ACID; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; ANTICOAGULANT AGENT;

ACID BASE BALANCE; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD VESSEL TONE; BONE METABOLISM; CITRIC ACID CYCLE; CLINICAL DECISION MAKING; CONTINUOUS HEMODIALYSIS; CONTINUOUS RENAL REPLACEMENT THERAPY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEART ARREST; HEART MUSCLE CONTRACTILITY; HUMAN; HYPOCALCEMIA; HYPOTENSION; INFLAMMATION; LACTIC ACIDOSIS; LIVER FAILURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SHOCK; SIDE EFFECT; BLOOD CLOTTING; DRUG EFFECTS; PROCEDURES; RENAL REPLACEMENT THERAPY;

ANTICOAGULANTS; BLOOD COAGULATION; CITRIC ACID; HUMANS; RENAL REPLACEMENT THERAPY;

EID: 84872266922     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11645     Document Type: Review

References (85)

1. van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 1996, 7:145-150.
2. Oudemans-Van Straaten HM, Kellum JA, Bellomo R. Clinical review: anticoagulation for continuous renal replacement therapy - heparin or citrate?. Crit Care 2011, 15:202. 3222015, 21345279.
3. Meier-Kriesche HU, Gitomer J, Finkel K, DuBose T. Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med 2001, 29:748-752. 10.1097/00003246-200104000-00010, 11373461.
4. Mitchell A, Daul AE, Beiderlinden M, Schafers RF, Heemann U, Kribben A, Peters J, Philipp T, Wenzel RR. A new system for regional citrate anticoagulation in continuous venovenous hemodialysis (CVVHD). Clin Nephrol 2003, 59:106-114.
5. Cointault O, Kamar N, Bories P, Lavayssiere L, Angles O, Rostaing L, Genestal M, Durand D. Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions. Nephrol Dial Transplant 2004, 19:171-178. 10.1093/ndt/gfg488, 14671053.
6. Gupta M, Wadhwa NK, Bukovsky R. Regional citrate anticoagulation for continuous venovenous hemodiafiltration using calcium-containing dialysate. Am J Kidney Dis 2004, 43:67-73. 10.1053/j.ajkd.2003.09.014, 14712429.
7. Balik M, Zakharchenko M, Otahal M, Hruby J, Polak F, Rusinova K, Stach Z, Vavrova J, Jabor A. Quantification of systemic delivery of substrates for intermediate metabolism during citrate anticoagulation of continuous renal replacement therapy. Blood Purif 2012, 33:80-87. 10.1159/000334641, 22212643.
8. Chadha V, Garg U, Warady BA, Alon US. Citrate clearance in children receiving continuous venovenous renal replacement therapy. Pediatr Nephrol 2002, 17:819-824. 10.1007/s00467-002-0963-6, 12376810.
9. Oudemans-Van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, Dijksman LM, Zandstra DF. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009, 37:545-552. 10.1097/CCM.0b013e3181953c5e, 19114912.
10. Betjes MG, van Oosterom D, van Agteren M, van de Wetering J. Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. J Nephrol 2007, 20:602-608.
11. Calatzis A, Toepfer M, Schramm W, Spannagl M, Schiffl H. Citrate anticoagulation for extracorporeal circuits: effects on whole blood coagulation activation and clot formation. Nephron 2001, 89:233-236. 10.1159/000046075, 11549910.
12. James MF, Roche AM. Dose-response relationship between plasma ionized calcium concentration and thrombelastography. J Cardiothorac Vasc Anesth 2004, 18:581-586. 10.1053/j.jvca.2004.07.016, 15578468.
13. Oudemans-Van Straaten HM, Wester JP, de Pont AC, Schetz MR. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?. Intensive Care Med 2006, 32:188-202. 10.1007/s00134-005-0044-y, 16453140.
14. Joannidis M, Oudemans-Van Straaten HM. Clinical review: Patency of the circuit in continuous renal replacement therapy. Crit Care 2007, 11:218. 10.1186/cc5937, 2206533, 17634148.
15. Mariano F, Morselli M, Bergamo D, Hollo Z, Scella S, Maio M, Tetta C, Dellavalle A, Stella M, Triolo G. Blood and ultrafiltrate dosage of citrate as a useful and routine tool during continuous venovenous haemodiafiltration in septic shock patients. Nephrol Dial Transplant 2011, 26:3882-3888. 10.1093/ndt/gfr106, 21385861.
16. Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 1990, 38:976-981. 10.1038/ki.1990.300, 2266683.
17. Kutsogiannis DJ, Gibney RT, Stollery D, Gao J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005, 67:2361-2367. 10.1111/j.1523-1755.2005.00342.x, 15882280.
18. Tolwani AJ, Prendergast MB, Speer RR, Stofan BS, Wille KM. A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance. Clin J Am Soc Nephrol 2006, 1:79-87.
19. Morgera S, Scholle C, Melzer C, Slowinski T, Liefeld L, Baumann G, Peters H, Neumayer HH. A simple, safe and effective citrate anticoagulation protocol for the genius dialysis system in acute renal failure. Nephron Clin Pract 2004, 98:c35-c40. 10.1159/000079925, 15361702.
20. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004, 30:260-265. 10.1007/s00134-003-2047-x, 14600809.
21. Tobe SW, Aujla P, Walele AA, Oliver MJ, Naimark DM, Perkins NJ, Beardsall M. A novel regional citrate anticoagulation protocol for CRRT using only commercially available solutions. J Crit Care 2003, 18:121-129. 10.1053/jcrc.2003.50006, 12800123.
22. Swartz R, Pasko D, O'Toole J, Starmann B. Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation. Clin Nephrol 2004, 61:134-143.
23. Shum HP, Chan KC, Yan WW. Regional citrate anticoagulation in predilution continuous venovenous hemofiltration using prismocitrate 10/2 solution. Ther Apher Dial 2012, 16:81-86. 10.1111/j.1744-9987.2011.01001.x, 22248200.
24. Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int 1999, 55:1991-1997. 10.1046/j.1523-1755.1999.00444.x, 10231464.
25. Dorval M, Madore F, Courteau S, Leblanc M. A novel citrate anticoagulation regimen for continuous venovenous hemodiafiltration. Intensive Care Med 2003, 29:1186-1189. 10.1007/s00134-003-1801-4, 12761615.
26. Gabutti L, Marone C, Colucci G, Duchini F, Schonholzer C. Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge. Intensive Care Med 2002, 28:1419-1425. 10.1007/s00134-002-1443-y, 12373466.
27. Thoenen M, Schmid ER, Binswanger U, Schuepbach R, Aerne D, Schmidlin D. Regional citrate anticoagulation using a citrate-based substitution solution for continuous venovenous hemofiltration in cardiac surgery patients. Wien Klin Wochenschr 2002, 114:108-114.
28. Egi M, Naka T, Bellomo R, Langenberg CC, Li W, Fealy N, Baldwin I. The acid-base effect of changing citrate solution for regional anticoagulation during continuous veno-venous hemofiltration. Int J Artif Organs 2008, 31:228-236.
29. Aman J, Nurmohamed SA, Vervloet MG, Groeneveld AB. Metabolic effects of citrate- vs bicarbonate-based substitution fluid in continuous venovenous hemofiltration: a prospective sequential cohort study. J Crit Care 2010, 25:120-127. 10.1016/j.jcrc.2009.02.013, 19427760.
30. Morgan TJ. The Stewart approach - one clinician's perspective. Clin Biochem Rev 2009, 30:41-54. 2702213, 19565024.
31. Palsson R, Laliberte KA, Niles JL. Choice of replacement solution and anticoagulant in continuous venovenous hemofiltration. Clin Nephrol 2006, 65:34-42.
32. Zhang Z, Hongying N. Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy. Intensive Care Med 2012, 38:20-28. 10.1007/s00134-011-2438-3, 22124775.
33. Fealy N, Baldwin I, Johnstone M, Egi M, Bellomo R. A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. Int J Artif Organs 2007, 30:301-307.
34. Wu MY, Hsu YH, Bai CH, Lin YF, Wu CH, Tam KW. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2012, 59:810-818. 10.1053/j.ajkd.2011.11.030, 22226564.
35. Hetzel GR, Schmitz M, Wissing H, Ries W, Schon G, Heering PJ, Isgro F, Kribben A, Himmele R, Grabensee B, Rump LC. Regional citrate versus systemic heparin for anticoagulation on critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant 2010, 26:232-239.
36. Chatham JC, Des RC, Forder JR. Evidence of separate pathways for lactate uptake and release by the perfused rat heart. Am J Physiol Endocrinol Metab 2001, 281:E794-E802.
37. Mazer CD, Stanley WC, Hickey RF, Neese RA, Cason BA, Demas KA, Wisneski JA, Gertz EW. Myocardial metabolism during hypoxia: maintained lactate oxidation during increased glycolysis. Metabolism 1990, 39:913-918. 10.1016/0026-0495(90)90300-2, 2202882.
38. Kline JA, Thornton LR, Lopaschuk GD, Barbee RW, Watts JA. Lactate improves cardiac efficiency after hemorrhagic shock. Shock 2000, 14:215-221. 10.1097/00024382-200014020-00023, 10947169.
39. Levy B, Mansart A, Montemont C, Gibot S, Mallie JP, Regnault V, Lecompte T, Lacolley P. Myocardial lactate deprivation is associated with decreased cardiovascular performance, decreased myocardial energetics, and early death in endotoxic shock. Intensive Care Med 2007, 33:495-502. 10.1007/s00134-006-0523-9, 17242933.
40. Leverve XM, Boon C, Hakim T, Anwar M, Siregar E, Mustafa I. Half-molar sodium-lactate solution has a beneficial effect in patients after coronary artery bypass grafting. Intensive Care Med 2008, 34:1796-1803. 10.1007/s00134-008-1165-x, 18563389.
41. Owen OE, Kalhan SC, Hanson RW. The key role of anaplerosis and cataplerosis for citric acid cycle function. J Biol Chem 2002, 277:30409-30412. 10.1074/jbc.R200006200, 12087111.
42. Weinberg JM, Venkatachalam MA, Roeser NF, Nissim I. Mitochondrial dysfunction during hypoxia/reoxygenation and its correction by anaerobic metabolism of citric acid cycle intermediates. Proc Natl Acad Sci USA 2000, 97:2826-2831. 10.1073/pnas.97.6.2826, 16014, 10717001.
43. Vary TC, Hazen S. Sepsis alters pyruvate dehydrogenase kinase activity in skeletal muscle. Mol Cell Biochem 1999, 198:113-118. 10.1023/A:1006993910781, 10497885.
44. Leverve XM, Mustafa I. Lactate: A key metabolite in the intercellular metabolic interplay. Crit Care 2002, 6:284-285. 10.1186/cc1509, 137304, 12225597.
45. Balik M, Zakharchenko M, Leden F, Otahal M, Hruby J, Polak F, Rusinova K, Zdenek S, Tokarik M, Jabor A, Oudemans-van Straaten HM. Bioenergetic gain of citrate anticoagulated continuous hemodiafiltration - a comparison between two citrate modalities and unfractionated heparin. J Crit Care 2012,
46. Andersson T, Dahlgren C, Pozzan T, Stendahl O, Lew PD. Characterization of fMet-Leu-Phe receptor-mediated Ca2+ influx across the plasma membrane of human neutrophils. Mol Pharmacol 1986, 30:437-443.
47. Dhondt A, Vanholder R, Tielemans C, Glorieux G, Waterloos MA, De SR, Lameire N. Effect of regional citrate anticoagulation on leukopenia, complement activation, and expression of leukocyte surface molecules during hemodialysis with unmodified cellulose membranes. Nephron 2000, 85:334-342. 10.1159/000045683, 10940744.
48. Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol 2003, 4:517-529. 10.1038/nrm1155, 12838335.
49. Tintinger GR, Steel HC, Theron AJ, Anderson R. Pharmacological control of neutrophil-mediated inflammation: Strategies targeting calcium handling by activated polymorphonuclear leukocytes. Drug Des Devel Ther 2009, 2:95-104. 2761182, 19920897.
50. Bohler J, Schollmeyer P, Dressel B, Dobos G, Horl WH. Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: dissociation of complement activation and neutropenia from neutrophil degranulation. J Am Soc Nephrol 1996, 7:234-241.
51. Bos JC, Grooteman MP, van Houte AJ, Schoorl M, van Limbeek J, Nube MJ. Low polymorphonuclear cell degranulation during citrate anticoagulation: a comparison between citrate and heparin dialysis. Nephrol Dial Transplant 1997, 12:1387-1393. 10.1093/ndt/12.7.1387, 9249774.
52. Gabutti L, Ferrari N, Mombelli G, Keller F, Marone C. The favorable effect of regional citrate anticoagulation on interleukin-1beta release is dissociated from both coagulation and complement activation. J Nephrol 2004, 17:819-825.
53. Gritters M, Grooteman MP, Schoorl M, Schoorl M, Bartels PC, Scheffer PG, Teerlink T, Schalkwijk CG, Spreeuwenberg M, Nube MJ. Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Nephrol Dial Transplant 2006, 21:153-159. 10.1093/ndt/gfi069, 16144857.
54. Ding F, Song JH, Jung JY, Lou L, Wang M, Charles L, Westover A, Smith PL, Pino CJ, Buffington DA, Humes HD. A biomimetic membrane device that modulates the excessive inflammatory response to sepsis. PLoS One 2011, 6:e18584. 10.1371/journal.pone.0018584, 3077371, 21533222.
55. Polanska K, Opatrny K, Rokyta R, Krouzecky A, Vit L, Kasal E. Effect of regional citrate anticoagulation on thrombogenicity and biocompatibility during CVVHDF. Ren Fail 2006, 28:107-118. 10.1080/08860220500530338, 16538967.
56. Tyrrell DJ, Horne AP, Holme KR, Preuss JM, Page CP. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999, 46:151-208.
57. Li Y, Sun JF, Cui X, Mani H, Danner RL, Li X, Su JW, Fitz Y, Eichacker PQ. The effect of heparin administration in animal models of sepsis: a prospective study in Escherichia coli-challenged mice and a systematic review and metaregression analysis of published studies. Crit Care Med 2011, 39:1104-1112. 10.1097/CCM.0b013e31820eb718, 3389754, 21317646.
58. Hochart H, Jenkins PV, Preston RJ, Smith OP, White B, O'Donnell J. Concentration-dependent roles for heparin in modifying lipopolysaccharide-induced activation of mononuclear cells in whole blood. Thromb Haemost 2008, 99:570-575.
59. Li X, Zheng Z, Li X, Ma X. Unfractionated heparin inhibits lipopolysaccharide-induced inflammatory response through blocking p38 MAPK and NF-kappaB activation on endothelial cell. Cytokine 2012, 60:114-121. 10.1016/j.cyto.2012.06.008, 22763042.
60. Zarychanski R, Doucette S, Fergusson D, Roberts D, Houston DS, Sharma S, Gulati H, Kumar A. Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med 2008, 36:2973-2979. 10.1097/CCM.0b013e31818b8c6b, 18824906.
61. Ding R, Zhao D, Guo R, Zhang Z, Ma X. Treatment with unfractionated heparin attenuates coagulation and inflammation in endotoxemic mice. Thromb Res 2011, 128:e160-e165. 10.1016/j.thromres.2011.07.044, 21851968.
62. Jaimes F, De La Rosa G, Morales C, Fortich F, Arango C, Aguirre D, Munoz A. Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study). Crit Care Med 2009, 37:1185-1196. 10.1097/CCM.0b013e31819c06bc, 19242322.
63. Gebska MA, Titley I, Paterson HF, Morilla RM, Davies DC, Gruszka-Westwood AM, Kakkar VV, Eccles S, Scully MF. High-affinity binding sites for heparin generated on leukocytes during apoptosis arise from nuclear structures segregated during cell death. Blood 2002, 99:2221-2227. 10.1182/blood.V99.6.2221, 11877301.
64. Gritters M, Borgdorff P, Grooteman MP, Schoorl M, Schoorl M, Bartels PC, Tangelder GJ, Nube MJ. Platelet activation in clinical haemodialysis: LMWH as a major contributor to bio-incompatibility?. Nephrol Dial Transplant 2008, 23:2911-2917. 10.1093/ndt/gfn137, 18364368.
65. Borawski J. Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: the underestimated modifying effects of heparin. Am J Kidney Dis 2006, 47:37-41. 10.1053/j.ajkd.2005.10.001, 16377383.
66. Hoffmann JN, Vollmar B, Laschke MW, Inthorn D, Kaneider NC, Dunzendorfer S, Wiedermann CJ, Romisch J, Schildberg FW, Menger MD. Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb Haemost 2002, 88:242-252.
67. Heinzelmann M, Bosshart H. Heparin binds to lipopolysaccharide (LPS)-binding protein, facilitates the transfer of LPS to CD14, and enhances LPS-induced activation of peripheral blood monocytes. J Immunol 2005, 174:2280-2287.
68. Jordan RE, Nelson RM, Kilpatrick J, Newgren JO, Esmon PC, Fournel MA. Antithrombin inactivation by neutrophil elastase requires heparin. Am J Med 1989, 87:19S-22S.
69. Bakker AJ, Boerma EC, Keidel H, Kingma P, van der Voort PH. Detection of citrate overdose in critically ill patients on citrate-anticoagulated venovenous haemofiltration: use of ionised and total/ionised calcium. Clin Chem Lab Med 2006, 44:962-966.
70. Hetzel GR, Taskaya G, Sucker C, Hennersdorf M, Grabensee B, Schmitz M. Citrate plasma levels in patients under regional anticoagulation in continuous venovenous hemofiltration. Am J Kidney Dis 2006, 48:806-811. 10.1053/j.ajkd.2006.07.016, 17060000.
71. Link A, Klingele M, Speer T, Rbah R, Poss J, Lerner-Graber A, Fliser D, Bohm M. Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients. Crit Care 2012, 16:R97. 10.1186/cc11363, 22643456.
72. Muller B, Becker KL, Kranzlin M, Schachinger H, Huber PR, Nylen ES, Snider RH, White JC, Schmidt-Gayk H, Zimmerli W, Ritz R. Disordered calcium homeostasis of sepsis: association with calcitonin precursors. Eur J Clin Invest 2000, 30:823-831. 10.1046/j.1365-2362.2000.00714.x, 10998084.
73. Zaloga GP, Sager A, Black KW, Prielipp R. Low dose calcium administration increases mortality during septic peritonitis in rats. Circ Shock 1992, 37:226-229.
74. Kramer L, Bauer E, Joukhadar C, Strobl W, Gendo A, Madl C, Gangl A. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med 2003, 31:2450-2455. 10.1097/01.CCM.0000084871.76568.E6, 14530750.
75. Apsner R, Schwarzenhofer M, Derfler K, Zauner C, Ratheiser K, Kranz A. Impairment of citrate metabolism in acute hepatic failure. Wien Klin Wochenschr 1997, 109:123-127.
76. Faybik P, Hetz H, Mitterer G, Krenn CG, Schiefer J, Funk GC, Bacher A. Regional citrate anticoagulation in patients with liver failure supported by a molecular adsorbent recirculating system. Crit Care Med 2011, 39:273-279. 10.1097/CCM.0b013e3181fee8a4, 20975551.
77. Meijers B, Laleman W, Vermeersch P, Nevens F, Wilmer A, Evenepoel P. A prospective randomized open-label crossover trial of regional citrate anticoagulation vs. anticoagulation free liver dialysis by the Molecular Adsorbents Recirculating System. Crit Care 2012, 16:R20. 10.1186/cc11180, 3396260, 22305273.
78. Slowinski T, Morgera S, Joannidis M, Kindgen-Milles D. Multicenter prospective observational study on safety and efficacy of regional citrate anticoagulation in CVVHD in the presence of liver failure: the Liver Citrate Anticoagulation Treshold Study (L-CAT). Crit Care 2011, 15(Suppl 1):P127.
79. Wang PL, Meyer MM, Orloff SL, Anderson S. Bone resorption and "relative" immobilization hypercalcemia with prolonged continuous renal replacement therapy and citrate anticoagulation. Am J Kidney Dis 2004, 44:1110-1114. 10.1053/j.ajkd.2004.09.001, 15558534.
80. van der Voort PH, Postma SR, Kingma WP, Boerma EC, de Heide LJ, Bakker AJ. An observational study on the effects of nadroparin-based and citrate-based continuous venovenous hemofiltration on calcium metabolism. Blood Purif 2007, 25:267-273. 10.1159/000101853, 17446700.
81. Brain M, Parkes S, Fowler P, Robertson I, Brown A. Calcium flux in continuous venovenous haemodiafiltration with heparin and citrate anticoagulation. Crit Care Resusc 2011, 13:72-81.
82. Thijssen S, Kruse A, Raimann J, Bhalani V, Levin NW, Kotanko P. A mathematical model of regional citrate anticoagulation in hemodialysis. Blood Purif 2010, 29:197-203. 10.1159/000245647, 20093827.
83. Szamosfalvi B, Frinak S, Yee J. Automated regional citrate anticoagulation: technological barriers and possible solutions. Blood Purif 2010, 29:204-209. 10.1159/000245648, 20093828.
84. Brandl M, Strobl K, Hartmann J, Kellner K, Posnicek T, Falkenhagen D. A target-orientated algorithm for regional citrate-calcium anticoagulation in extracorporeal therapies. Blood Purif 2012, 33:7-20. 10.1159/000332394, 22085810.
85. Kidney Disease: Improving Global Outcomes (KDIGO). , http://www.kdigo.org/